Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 2,614 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman sold 2,614 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $127.68, for a total transaction of $333,755.52. Following the transaction, the director now owns 7,969 shares in the company, valued at $1,017,481.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Natera Trading Up 2.5 %

Shares of NTRA stock traded up $3.16 during trading hours on Monday, hitting $129.67. The company had a trading volume of 1,343,863 shares, compared to its average volume of 1,374,068. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a market capitalization of $15.92 billion, a PE ratio of -41.56 and a beta of 1.53. The company’s fifty day moving average is $112.73 and its 200 day moving average is $104.17. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $132.01.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period last year, the business posted ($0.97) earnings per share. Research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NTRA. Norges Bank purchased a new position in Natera in the 4th quarter valued at approximately $83,970,000. Perceptive Advisors LLC increased its holdings in Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after purchasing an additional 632,047 shares during the period. Vanguard Group Inc. raised its position in Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares in the last quarter. Farallon Capital Management LLC boosted its stake in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after buying an additional 532,874 shares during the period. Finally, First Light Asset Management LLC grew its position in shares of Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after buying an additional 490,822 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Robert W. Baird boosted their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Stephens reissued an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. Piper Sandler restated an “overweight” rating and issued a $150.00 target price on shares of Natera in a report on Friday. UBS Group reduced their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.